This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Medpace (MEDP) is a Great Momentum Stock: Should You Buy?
by Zacks Equity Research
Does Medpace (MEDP) have what it takes to be a top stock pick for momentum investors? Let's find out.
Top Ranked Momentum Stocks to Buy for August 20th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, August 20th.
Zacks Industry Outlook Highlights: Medpace Holdings, AMN Healthcare Services, LHC Group and Surgery Partners
by Zacks Equity Research
Zacks Industry Outlook Highlights: Medpace Holdings, AMN Healthcare Services, LHC Group and Surgery Partners
The Zacks Analyst Blog Highlights: Houghton Mifflin Harcourt Company, CoreLogic, FTI Consulting, Artisan Partners Asset Management and Medpace Holdings
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Houghton Mifflin Harcourt Company, CoreLogic, FTI Consulting, Artisan Partners Asset Management and Medpace Holdings
Near-Term Outlook Tepid for Medical Services Industry
by Urmimala Biswas
This sector witnesses growing demand for telemedicine-focused online medical services amid the pandemic.
Service Side of US Economy is Up and Running: 5 Top Picks
by Tirthankar Chakraborty
The service sector index read 58.1% in July, a 17-month high. Lest we forget, a reading above 48.5% indicates expansion of the broader economy.
Bet on These 5 Low Leverage Stocks This Earnings Season
by Zacks Equity Research
Debt is something that gives you the chills since it brings with it the burden of repayment with additional interest in the future. So investors should choose stocks prudently
3 Reasons Why Medpace (MEDP) Is a Great Growth Stock
by Zacks Equity Research
Medpace (MEDP) possesses solid growth attributes, which could help it handily outperform the market.
Medpace (MEDP) Q2 Earnings and Revenues Top Estimates (Revised)
by Zacks Equity Research
Medpace (MEDP) delivered earnings and revenue surprises of 61.90% and 13.50%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Medpace (MEDP) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
Medpace (MEDP) delivered earnings and revenue surprises of 52.38% and 13.50%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Is a Surprise Coming for Medpace (MEDP) This Earnings Season?
by Zacks Equity Research
Medpace (MEDP) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Medpace (MEDP) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Medpace (MEDP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Medpace (MEDP) Q1 Earnings Miss Estimates
by Zacks Equity Research
Medpace (MEDP) delivered earnings and revenue surprises of -1.30% and 1.24%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Teladoc (TDOC) Up 49% Year to Date: Will the Rally Continue?
by Zacks Equity Research
Teladoc (TDOC) benefits from its fast growing healthcare business and international expansion.
Company News for Feb 26, 2020
by Zacks Equity Research
Companies In The News Are: HPQ, KEYS, MEDP, MIC.
Medpace (MEDP) Surpasses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Medpace (MEDP) delivered earnings and revenue surprises of 13.33% and 3.51%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Medpace (MEDP) Q3 Earnings Meet Estimates
by Zacks Equity Research
Medpace (MEDP) delivered earnings and revenue surprises of 0.00% and -0.24%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Medpace (MEDP) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Medpace (MEDP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Should First Trust Small Cap Growth AlphaDEX Fund (FYC) Be on Your Investing Radar?
by Sweta Killa
Style Box ETF report for FYC
Should Teladoc Worry About Amazon's Virtual Healthcare Move?
by Zacks Equity Research
Teladoc (TDOC) might face increasing competition from Amazon in virtual healthcare space once the latter expands its presence.
The Zacks Analyst Blog Highlights: RH, PennyMac, Medpace, Mercury Systems and Lithia
by Zacks Equity Research
The Zacks Analyst Blog Highlights: RH, PennyMac, Medpace, Mercury Systems and Lithia
5 Must-Buy Mid-Cap Stocks Amid Global Economic Fluctuations
by Nalak Das
Investment in mid-cap stocks is often recognized as a good portfolio diversification strategy during market fluctuations.
U.S. Private Sector Adds New Jobs: 5 Gainers
by Zacks Equity Research
Nonfarm payroll reports show jobs addition in the private sector, these are five stocks to add to your portfolio.
Teladoc Gains on Growing Acceptance for TeleHealth Services
by Zacks Equity Research
Teladoc's (TDOC) extensive ecosystem and infrastructure poise it well for long-term growth in the expanding telehealth industry.
Medpace (MEDP) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
Medpace (MEDP) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.